Technology
Health
Biotechnology

Biofrontera

$12.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.40 (3.33%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Biofrontera and other stocks, options, ETFs, and crypto commission-free!

About

Biofrontera AG American Depositary Shares, also called Biofrontera, is a biopharmaceutical company, which engages in the development, sale, and distribution of dermatological drugs and medical cosmetics for the care, protection, and treatment of the skin. Its products are used for the treatment of chronic, antihistamine refractory urticaria, and migraine prophylaxis. Read More The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Employees
119
Headquarters
Leverkusen, Nordrhein-Westfalen
Founded
1997
Market Cap
270.06M
Price-Earnings Ratio
Dividend Yield
Average Volume
3.39K
High Today
Low Today
Open Price
Volume
0.00
52 Week High
$17.00
52 Week Low
$11.04

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Cosmetics
Pharmaceutical
Retail

News

Markets InsiderMar 6

DGAP-PVR: Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP Voting Rights Announcement: Biofrontera AG Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 06.03.2019 / 09:27 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: Biofrontera AG Street: Hemmelrather Weg 201 Postal code...

3
Seeking AlphaFeb 26

Biofrontera: Why This Small German Company Can Become The Next Hot Stock

Biofrontera has a very good chance to keep up the steep growth due to many factors, especially the outstanding market opportunity for Ameluz.

24

Earnings

Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 15, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.